🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🌞 Good morning, #ASCO25! Before diving into today’s sessions, let’s recap the groundbreaking studies from yesterday’s plenary and breast cancer presentations. Here’s a quick summary of the highlights:

At #ASCO25 discussion on Destiny-Breast09 T-DXd + pertu is a highly effective regimen in 1️⃣st line Questions remain on optimal sequencing (shall we use “high-risk” selection factors for T-DXd+P 1st L?) and duration (T-DXd + P induction followed by HP maintenance?) OncoAlert

Association between BRCA1/2 pathogenic/likely pathogenic variants and outcomes in young #breastcancer Excellent job presented by super Angela Toss #ASCO25 Another great contribution related to the BCY initiative led by amazing Matteo Lambertini, MD PhD OncoAlert #OncoAlert

🫀 Cardiovascular toxicity is a growing concern in #breastcancer survivorship In our latest ESMO Open review, we outline strategies for prevention, early detection and management 🔗sciencedirect.com/science/articl… Evandro de Azambuja, MD, PhD Elisa Agostinetto OncoAlert

Happening NOW at #ASCO25 !! Poster presented by Guilherme Nader Marta on long-term outcomes of patients with HER2-positive invasive lobular carcinoma in the #ALTTOtrial ! Go check poster 135! Institut Jules Bordet Instituut Dana-Farber Harvard University

Original Article: Structured Exercise after Adjuvant Chemotherapy for Colon Cancer (CHALLENGE phase 3 trial) nej.md/4mh5RPL #ASCO25 | ASCO

In PEACE-3 (EORTC 1333), the addition of 6 cycles of Ra223 to enzalutamide improves PSA response time and rates (≥90%), ALP reduction time (≥30%), and ALP normalization at 6 and 12 months. EORTC silke gillessen Andrey Soares GETUG CancerTrialsIreland 🌈 SOGUG

At #ASCO25 Clinical Science Symposium Angela Toss🇮🇹presented new insights from the 🌍BRCA BCY collab on the impact of BRCA variant #types in young pts with BC (n=3,294) Key findings: Truncating BRCA 1 PVs = worse OS Missense BRCA1/2 PVs = better OS Matteo Lambertini, MD PhD OncoAlert

📌 Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: 🔸A pooled analysis of three WSG trials. ✨Monika Karla Graeser, MD OncoAlert #OncoAlertAF #ASCO25

One more NEJM paper for the #BreastCancer community at #ASCO25: very important data with use of #elinzanetant to help patients struggling with vasomotor symptoms during endocrine therapy OncoAlert

With synchronous publication in NEJM, Fatima Cardoso ABC Global Alliance shows Elinzanetant reduces vasomotor symptoms (hot flashes) for patients on ET with HR+ BC #ASCO25

✨ That’s a wrap on #ESTROAgora25! Huge thanks to all participants, mentors, and organisers who made this space such a vibrant hub of exchange, creativity, and connection. Your energy made the Agora truly special. We can't wait to see how these ideas evolve and grow! 💡🌱

We are grateful to our ~44,000 attendees who made #ASCO25 a success & the place to be! With nearly 40% joining us from outside the U.S., we are truly a global community united by our shared goal of improving #CancerCare & pt outcomes around the world. A heartfelt ‘thank you.’ 💗

NSABP B-51: RNI vs no RNI in ypN0 after neoadjuvant chemo (cT1-T3N1) 5y iBCRF➡️92.7% vs 91.8% 5y OS➡️93.6% vs 94.0% 💥No clear benefit from RNI in patients downstaged to ypN0 📌HR+/HER2– needs longer follow-up 📌TNBC may even fare worse with RNI nejm.org/doi/full/10.10…

The elections for directors are open until June 10! Your vote truly matters and plays a vital role in shaping the future of our community. Join us by casting your vote and making a real difference! ESMO - Eur. Oncology FabriceAndre Andres Cervantes G Curigliano MD PhD Vote now: ow.ly/XX3W50VZQyL

📢 Join us for the joint session with ESC at #ESCardioOnco2025! 🗓 20 June | 🕔 17:20–18:15 📍 Room 1 | Track: Pharmacology of Cancer Drugs With top experts: 🟢 Peter Van Der Meer (UMC Groningen) 🟢 Icro Meattini (Univ. of Florence) 🔗 bit.ly/4kMyWky #ESCcardio

Axillary Management After Neoadjuvant Systemic Therapy From Dr. Mediget Teshome's wonderful presentation👇 #ASCO25

DEAR COLLEAGUES🚨 You are warmly invited to watch the Top Trials of the Year, presented by some of the world’s leading experts. JUST CLICK AND WATCH ⭐ GU Oncology buff.ly/3hkYYG6 ⭐ #BreastCancer buff.ly/EH7RPPc ⭐ #LungCancer 🫁 @Mascc #SupportiveCare

Really grateful for another successful #YBO event in beautiful #genova…definitely a bright future ahead for 🇮🇹 with such an excellent and motivated young #BreastCancer community ❤️🤩🔝💪 Università di Genova Ospedale San Martino Genova Luca Arecco, MD OncoAlert

‼️REGISTER 👉🏻OncoAlert360.com OR 👉🏻buff.ly/48Xpgz0 📩📩📩 The OncoAlert🚨NEWSLETTER ⭐️THE COMPLETE #ASCO25 EDITION⭐️ OUR PICKS FROM THE ENTIRE CONGRESS and Special VIDEO insights from our collaborators on specific trials OUT On MONDAY June 9, 2025 !! ⬇️⬇️⬇️